Detail akcie Circassia online

Business Summary: NIOX Group plc is a United Kingdom-based diagnostics and management company that is focused on asthma. The Company's product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The Company offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The Company offers products and services in around 50 countries.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Niox Group PLC revenues increased 18% to L36.8M. Net income before extraordinary items decreased 33% to L9.5M. Revenues reflect Asia Pacific segment increase of 29% to L13.8M, EU segment increase of 8% to L10.3M, US segment increase of 7% to L8.7M. Net income was offset by Operating-Head office costs segment loss increase of 50% to L4.5M. Dividend per share totaled to L0.01.